Adynxx drug failed in PhII but it’s going into PhIII anyway; Deerfield leads $50M raise for Sollis
→ San Francisco-based Adynxx says that their Phase II study for a new non-opioid pain drug failed — but they’re going into Phase III in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
